Lilly Arxxant retinopathy NDA in 2005
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly plans to submit an NDA "at the end of 2005" for use of ruboxistaurin (Arxxant) in diabetic retinopathy, the firm says Aug. 2. Lilly no longer plans to seek an indication for treatment of symptoms of diabetic peripheral neuropathy due to the protein kinase C-beta inhibitor's failure to meet its primary endpoint in two Phase III trials. An NDA had been planned for the second half of 2005 (1Pharmaceutical Approvals Monthly May 2005, In Brief). However, the company is continuing a Phase III trial looking at treatment of nerve dysfunction in DPN, slated to be complete in 2007. A study in diabetic macular edema is expected to complete in 2010...
You may also be interested in...
Lilly Plans To File Arxxant NDA On Strength Of Single Phase III Trial
Lilly will include only one Phase III study in an application for Arxxant use for diabetic retinopathy, the firm said
Lilly Arxxant for diabetic neuropathy
NDA for Lilly's protein kinase C inhibitor ruboxistaurin for treatment of diabetic peripheral neuropathy is slated for the second half of 2005, the company says during an April 18 earnings call. The firm is proposing the trade name Arxxant...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.